| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
|
| [2] |
Chen ZH, Zhang XP, Feng JK, et al. Actual long-term survival in hepatocellular carcinoma patients with microvascular invasion: a multicenter study from China[J]. Hepatol Int, 2021, 15(3):642-650.
|
| [3] |
Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1):6.
|
| [4] |
Will CL, Lührmann R. Spliceosome structure and function[J]. Cold Spring Harb Perspect Biol, 2011, 3(7):a003707.
|
| [5] |
Millevoi S, Loulergue C, Dettwiler S, et al. An interaction between U2AF 65 and CFIm links the splicing and 3' end processing machineries[J]. Embo J, 2006, 25(20):4854-4864.
|
| [6] |
Wang LL, Ruan Y, Wu X, et al.lncRNA ZFAS1 promotes HMGCR mRNA stabilization via binding U2AF2 to modulate pancreatic carcinoma lipometabolism[J]. J Immunol Res, 2022:4163198.
|
| [7] |
Li J, Cheng D, Zhu M, et al. OTUB2 stabilizes U2AF2 to promote the Warburg effect and tumorigenesis via the AKT/mTOR signaling pathway in non-small cell lung cancer[J]. Theranostics, 2019, 9(1):179-195.
|
| [8] |
Li Y, Chen S, Zhang X, et al. U2 small nuclear RNA auxiliary factor 2,transcriptionally activated by the transcription factor Dp-1/E2F transcription factor 1 complex, enhances the growth and aerobic glycolysis of leiomyosarcoma cells[J]. Bioengineered, 2022, 13(4):10200-10212.
|
| [9] |
Zhang P, Feng S, Liu G, et al. CD82 suppresses CD44 alternative splicing-dependent melanoma metastasis by mediating U2AF2 ubiquitination and degradation[J]. Oncogene, 2016, 35(38):5056-5069.
|
| [10] |
Zhang X, Bustos MA, Gross R, et al. Interleukin enhancer-binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma[J]. Clin Transl Med, 2021, 11(10):e608.
|
| [11] |
Jiang Y, Zhou J, Zhao J, et al. The U2AF2/circRNA ARF1/miR-342-3p/ISL2 feedback loop regulates angiogenesis in glioma stem cells[J]. J Exp Clin Canc Res, 2020, 39(1):182.
|
| [12] |
Han T, Gao M, Wang X, et al. LINC00665 activates Wnt/β-catenin signaling pathway to facilitate tumor progression of colorectal cancer via upregulating CTNNB1[J]. Exp Mol Pathol, 2021(120):104639.
|
| [13] |
Fang L, Ye T, An Y. Circular RNA FOXP1 induced by ZNF263 upregulates U2AF2 expression to accelerate renal cell carcinoma tumorigenesis and Warburg effect through sponging miR-423-5p[J]. J Immunol Res, 2021:8050993.
|
| [14] |
Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease[J]. Nat Rev Mol Cell Biol, 2020, 21(4):183-203.
|
| [15] |
Liu R, Chen YW, Liu GZ, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers[J]. Cell Death Dis, 2020, 11(9):797.
|
| [16] |
Xu ZR, Han X, Ou DM, et al. Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy[J]. Appl Microbiol Biotechnol, 2020, 104(2):575-587.
|
| [17] |
Yi JM, Zhu JJ, Wu J, et al. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis[J]. Proc Natl Acad Sci U S A, 2020, 117(49):31189-31197.
|
| [18] |
Zou ZL, Tao T, Li HM, et al. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges[J]. Cell Biosci, 2020(10):31.
|
| [19] |
Artemenko M, Zhong SSW, To SKY, et al. p70 S6 kinase as a therapeutic target in cancers: more than just an mTOR effector[J]. Cancer Lett, 2022(535):215593.
|
| [20] |
Fan QW, Nicolaides TP, Weiss WA. Inhibiting 4EBP1 in glioblastoma[J]. Clin Cancer Res, 2018, 24(1):14-21.
|
| [21] |
Hua H, Kong QB, Zhang HY, et al. Targeting mTOR for cancer therapy[J]. J Hematol Oncol, 2019, 12(1):71.
|